Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$199.33+2.54 (+1.29%)
Close on Nov 19, 2026Market cap $79.58BP/E –Yield –
Moderna net income
Net income is the profit left for shareholders after every expense, interest and tax.
Moderna's net income for the twelve months ending Jun 30, 2026 was -$3.15B. For fiscal 2025 it was -$2.82B. The highest annual figure on record is $12.20B in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.82B | – |
| FY2024 | Dec 31, 2024 | -$3.56B | – |
| FY2023 | Dec 31, 2023 | -$4.71B | -156.4% |
| FY2022 | Dec 31, 2022 | $8.36B | -31.5% |
| FY2021 | Dec 31, 2021 | $12.20B | – |
| FY2020 | Dec 31, 2020 | -$747.00M | – |
| FY2019 | Dec 31, 2019 | -$514.00M | – |
| FY2018 | Dec 31, 2018 | -$384.73M | – |
| FY2017 | Dec 31, 2017 | -$255.92M | – |
| FY2016 | Dec 31, 2016 | -$216.21M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$782.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.34B | – |
| Q4 FY2025 | Dec 31, 2025 | -$826.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$200.00M | -1638.5% |
| Q2 FY2025 | Jun 30, 2025 | -$825.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$971.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.12B | -616.1% |
| Q3 FY2024 | Sep 30, 2024 | $13.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.28B | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.18B | -1587.3% |
| Q4 FY2023 | Dec 31, 2023 | $217.00M | -85.2% |
| Q3 FY2023 | Sep 30, 2023 | -$3.63B | -448.0% |
| Q2 FY2023 | Jun 30, 2023 | -$1.38B | -162.8% |
| Q1 FY2023 | Mar 31, 2023 | $79.00M | -97.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.47B | -69.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.04B | -68.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.20B | -21.0% |
| Q1 FY2022 | Mar 31, 2022 | $3.66B | +199.5% |
| Q4 FY2021 | Dec 31, 2021 | $4.87B | – |
| Q3 FY2021 | Sep 30, 2021 | $3.33B | – |
| Q2 FY2021 | Jun 30, 2021 | $2.78B | – |
| Q1 FY2021 | Mar 31, 2021 | $1.22B | – |
| Q4 FY2020 | Dec 31, 2020 | -$273.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$233.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$117.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$124.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$123.27M | – |
| Q3 FY2019 | Sep 30, 2019 | -$123.22M | – |
| Q2 FY2019 | Jun 30, 2019 | -$134.94M | – |
| Q1 FY2019 | Mar 31, 2019 | -$132.58M | – |
| Q4 FY2018 | Dec 31, 2018 | -$141.43M | – |
| Q3 FY2018 | Sep 30, 2018 | -$80.33M | – |
| Q2 FY2018 | Jun 30, 2018 | -$90.60M | – |
| Q1 FY2018 | Mar 31, 2018 | -$72.38M | – |
See a number that looks wrong?